{"url_path":"/sec/antx/8-k/2026-06-04/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1880438/0001193125-26-257430-index.html","accession_number":"0001193125-26-257430","cik":"0001880438","ticker":"ANTX","issuer_name":"AN2 Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1880438/0001193125-26-257430-index.html","primary_entity_key":"0001880438","primary_entity_name":"AN2 Therapeutics, Inc."},"word_count":166,"has_tables":true,"body_markdown":"Item 7.01.\n\nRegulation FD Disclosure.\n\nOn June 4, 2026, AN2 Therapeutics, Inc. (the “Company” or “AN2”) announced positive results from two studies evaluating the Company’s oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) caused by infection with the parasite T. cruzi. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information set forth in this Item 7.01 and in the press release attached hereto as Exhibit 99.1 is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent that the Company specifically incorporates it by reference."}